Evidence map›Paper›PMID 41408960›Full record

ReviewEuropean journal of haematology2026

Factors Affecting Immune Reconstitution Post-Allogeneic HSCT in Children: The Case for an Individualized Approach to Vaccination.

Hélène Buvelot, Frederic Baleydier, Laure Pittet, Geraldine Blanchard-Rohner

Abstract readReview
In one paragraph

Review in European journal of haematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Hélène BuvelotCentre for Vaccinology, Geneva University Hospital, Geneva, Switzerland.ORCID https://orcid.org/0009-0003-2963-1332
Frederic BaleydierDivision of Pediatric Oncology and Hematology, Department of Women, Child, and Adolescent, Geneva University Hospitals, Geneva, Switzerland.
Laure PittetUnit of Immunology, Vaccinology, and Rheumatology, Division of General Pediatrics, Department of Pediatrics, Gynecology and Obstetrics, Geneva University Hospitals, University of Geneva, Geneva, Switzerland.
Geraldine Blanchard-RohnerUnit of Immunology, Vaccinology, and Rheumatology, Division of General Pediatrics, Department of Pediatrics, Gynecology and Obstetrics, Geneva University Hospitals, University of Geneva, Geneva, Switzerland.ORCID https://orcid.org/0000-0002-9974-2172

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Allogeneic hematopoietic stem cell transplantation (HSCT) is increasingly used to treat malignant and non-malignant diseases. Following allogeneic HSCT, patients are particularly vulnerable to vaccine-preventable diseases (VPD) because conditioning depletes immune cells, including memory cells. Revaccination is therefore essential, but multiple factors, such as conditioning regimen, stem cell source, HLA compatibility, graft-versus-host-disease (GVHD), and age, affect immune reconstitution and vaccine response. Current guidelines recommend uniform vaccination schedule for all allogeneic HSCT patients, despite this heterogeneity. In this review, we discuss how these factors influence immune reconstitution and vaccine response, and highlights the need for a more individualized approach. Based on current evidence, we propose that vaccine timing, particularly for inactivated vaccines, could benefit from adjustment according to immune recovery markers, such as lymphocyte counts and presence of GVHD, rather than relying on fixed post-HSCT timepoints. We also discuss emerging immunotherapies, including CAR-T cells and bispecific antibodies, which can induce similarly prolonged immunosuppression and may benefit from personalized vaccination strategies. Further studies in pediatric populations are needed to define immunological threshold that would enable safer and more effective personalized vaccination schedules.

Indexed as

Hematopoietic Stem Cell TransplantationImmune ReconstitutionVaccinationChildGraft vs Host DiseaseHumansPrecision MedicineTransplantation ConditioningTransplantation, HomologousHSCTimmune reconstitutionvaccinationvaccine response

Identifiers

PMID41408960
PMCPMC12958788

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.